Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MDxHealthMDXH -1.90%49 Debt-to-EBITDA is 10.71 as of Mar. 2026. GuruFocus rates MDXH with a GF Score™ of 49/100 and a GF Value™ of $2.20 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 114 Medical Diagnostics & Research companies, MDxHealth ranks worse than 877192.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for MDxHealth's Debt-to-EBITDA or its related term are showing as below:
MDXH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.26 Med: -0.65 Max: -0.02
Current: -12.26
During the past 13 years, the highest Debt-to-EBITDA Ratio of MDxHealth was -0.02. The lowest was -12.26. And the median was -0.65.
MDXH's Debt-to-EBITDA is ranked worse than 100% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.31
vs MDXH: -12.26
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
MDxHealth Debt-to-EBITDA Related Terms
MDxHealth Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for MDxHealth's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MDXH vs AWHL, QUCY, BIOQ: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, MDxHealth's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MDxHealth Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MDxHealth's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
MDxHealth (MDXH) has a Debt-to-EBITDA of 10.71 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MDxHealth. According to the industry distribution chart, MDxHealth ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry.
Is MDxHealth's Debt-to-EBITDA too high?
MDxHealth's current Debt-to-EBITDA is 10.71. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.31. MDxHealth's value of 10.71 is 363.6% above this industry median. Based on the distribution chart, MDxHealth ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, MDxHealth has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's Debt-to-EBITDA compare to AWHL and QUCY?
According to the Medical Diagnostics & Research industry distribution chart, MDxHealth ranks #999999 out of 114 companies for Debt-to-EBITDA. This places MDxHealth in the lower half of its industry. The industry median Debt-to-EBITDA is 2.31. MDxHealth's value of 10.71 is 363.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.31, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MDxHealth's current Debt-to-EBITDA of 10.71 is 363.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on MDxHealth. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MDxHealth's current Debt-to-EBITDA is 10.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
Based on GuruFocus' analysis, MDxHealth (MDXH) is currently considered Possible Value Trap. The stock's GF Value™ is $2.20, compared to a current price of $0.44 — trading 80.2% below its estimated fair value. The current Debt-to-EBITDA is 10.71 and 363.6% above the Medical Diagnostics & Research industry median of 2.31. MDxHealth's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For MDxHealth (MDXH), the current Debt-to-EBITDA is 10.71 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MDxHealth (MDXH) Overvalued in 2026?
Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued.
The current stock price of $0.44 is trading 80.2% below its estimated GF Value™ of $2.20.
GuruFocus considers MDxHealth to be Possible Value Trap.
Key valuation signals for MDXH:
Debt-to-EBITDA: 10.71
GF Value™: $2.20 vs. price of $0.44 (80.2% below fair value)
Industry Position: 363.6% above the Medical Diagnostics & Research median (#999999 of 114)
No single metric tells the full story. See the MDXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
49GF Score
Get the complete analysis for MDXH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXH has been successfully added to your 
